MedTrace Logo

Oral Bioavailability of GLPG0555 in Different Solid Formulations

NCT01278095 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2011-03-24

No results posted yet for this study

Summary

The purpose of the study is to compare the pharmacokinetics of a solid capsule formulation of GLPG0555 with a nanosuspension, and to assess safety and tolerability of a single dose of GLPG0555.

Conditions

  • Healthy

Interventions

DRUG

GLPG0555 solid dispersion

solid dispersion capsules, 50 mg, single dose

DRUG

GLPG0555 nanosuspension

Nanosuspension, 50 mg, single dose

Sponsors & Collaborators

  • Galapagos NV

    lead INDUSTRY

Principal Investigators

  • Gerben van 't Klooster, PhD · Galapagos NV

  • Jos Leempoels, MD · SGS Stuivenberg

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-02-28
Completion
2011-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01278095 on ClinicalTrials.gov